While I have previously recognized lenzilumab's potential to enhance CAR-T efficacy as it may relate to TeraImmune, I think Gracell's CAR-T technology expands on that, and illustrates a broader scope for lenz in CAR-T.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.